



The current landscape of biosimilar development

Trends in the development of biosimilars


Key analytical techniques used to demonstrate biosimilarity included:




The proportion of preclinical studies performed in the development of biosimilars:




The main challenges faced when developing biosimilars included:



The main challenges of gaining regulatory approval for a biosimilar included:



The proportion who follow a one assay versus a two assay approach for PK bioanalytical assays included:




Key documentation followed to characterize bioanalytical similarity for PK assays included:




The proportion who follow a one assay versus a two assay approach for ADA bioanalytical assays included:




Key documentation followed to characterize bioanalytical similarity for ADA assays included:



Are current regulatory expectations sufficiently clear?



Key parts of biosimilar research that are outsourced versus not-outsourced included:




The future of biosimilar research



The cost of manufacturing biosimilars over the last 5 years has:



In the next 5 years, the percentage of approved biosimilars will:



Demographic of respondents



This infographic has been created as part of a Bioanalysis Zone feature in association with LabCorp.